Research
Gemcitabine Plus Paclitaxel vs Gemcitabine Alone after FOLFIRINOX in Metastatic Pancreatic Cancer
GEMPAX was an open-label (both researchers and patients know which treatment is being administered), randomised (randomly assigns participants in...
Predictive Values of Blood-based RNA Signature for the FOLFIRINOX/FOLFOX Response in Advanced Pancreatic Cancer
Presently, no widely recognised or established biomarkers are specifically designed to predict the effectiveness of FOLFIRINOX/FOLFOX (chemotherape...
DIPLOMA Trial: Minimally Invasive Surgery is an Effective Treatment Option for Early-Stage Pancreatic Cancer
A notable study, DIPLOMA, led by Abu Hilal, M.D., Ph.D., of the Istituto Ospedaliero Fondazione Poliambulanza in Brescia, Italy, involved a large c...
Personalized mRNA Pancreatic Cancer Vaccine Shows Promising Results in Small Trial
Messenger RNA (mRNA) vaccines – famous for preventing symptomatic infection of COVID-19—are starting to show some promise against pancreati...
ESMO Study Confirms Precision Oncology Remains Largely Inaccessible to European Cancer Patients
As a European umbrella organisation, DiCE is vocal in addressing the disparities associated with cancer patients’ access to precision medicin...
Primary and Updated Analyses for DESTINY-Gastric02 Study: Trastuzumab Deruxtecan Continues to Demonstrate Benefit in Metastatic Gastric and Gastro-oesophageal Cancer
Human Epidermal Growth receptor 2 (HER2) is a protein involved in normal cell growth, found in small amounts in almost all human cells, including s...
RWE Research in mCRC
In a recent article published in the Future Oncology, Patient Advocates and DiCE CEO Zorana Maravic explored and enhanced the understanding of the ...
EU Commission Approval of Tibsovo® (Ivosidenib) in IDH1-mutated Cholangiocarcinoma
The European Commission approved the use of Tibsovo® (Ivosidenib) as monotherapy for the treatment of locally advanced or metastatic cholangiocarc...
Liver Cancer Index – The Mapping Survey Is Available Online
The survey was created to map the liver cancer treatment landscape across the EU and is now available online and disseminated among several relevan...
Primary Findings From The GLOW Study Signals Positive Momentum In The Development Of Novel Therapeutic Options For Patients With HER2-Negative Locally Advanced Unresectable Or Metastatic Gastric & GEJ Cancers
At the end of 2022, leaders of the Phase 3 clinical trial GLOW shared their positive primary findings. GLOW (NCT03653507) is a global, multicenter,...